NMDP BioTherapies Introduces Enhanced Cellular Materials for Allogeneic Cell Therapy Development

MINNEAPOLIS--(BUSINESS WIRE)--NMDP BioTherapies℠, formerly Be The Match BioTherapies, a leader in cell and gene therapy development support, unveiled substantial upgrades to its cellular starting material offerings, including incorporating a Drug Master File (DMF) with its rapid-delivery, standard GMP leukopak to simplify regulatory filings. The strategic enhancements to its suite are designed to address the evolving needs of the allogeneic cell therapy industry, emphasizing optimized delivery